Efficacy and safety of first‐line regimens for advanced HER2‐positive breast cancer: A Bayesian network meta‐analysis

Documenti analoghi

• Integrative analyses identified gap junction beta‐2 as a prognostic biomarker and therapeutic target for breast cancer
  di: Di Zhang, et al.
  Pubblicazione: (2024)
• Inetetamab combined with sirolimus and chemotherapy for the treatment of HER2‐positive metastatic breast cancer patients with abnormal activation of the PI3K/Akt/mTOR pathway after trastuzumab treatment
  di: Qiao Li, et al.
  Pubblicazione: (2024)
• Development and validation of the NCC‐BC‐A scale to assess patient‐reported outcomes for breast cancer patients in China
  di: Fei Ma, et al.
  Pubblicazione: (2024)
• Breast cancer immunotherapy: Realities and advances
  di: Aixa Medina, et al.
  Pubblicazione: (2024)
• Synergistic effect of additional anlotinib and immunotherapy as second‐line or later‐line treatment in pancreatic cancer: A retrospective cohort study
  di: Boyu Qin, et al.
  Pubblicazione: (2024)